ALMR stock forecast, quote, news & analysis
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis... Show more
Why Alamar Biosciences (ALMR) Stock Is Down -19% in the Last 30 Days
Key Takeaways
- Alamar Biosciences (ALMR) shares fell roughly 19% over the trailing 30 days, from about $34.85 to $28.16, as the stock gave back a sharp early-autumn rally.
- The primary catalyst was the expiration of the company's six-month IPO lock-up on October 14, 2026, which allowed early investors to begin selling shares.
- The decline followed a run to a record intraday high of $39.61 in early October, meaning much of the pullback reflects profit-taking and supply overhang rather than weakening fundamentals.
- Despite the slide, Alamar's underlying business remained strong, with second-quarter 2026 revenue up 82% year over year and full-year guidance of $116 million to $120 million.
- The next major catalyst is the company's third-quarter earnings report, scheduled for November 3, 2026.
Alamar Biosciences (ALMR) Company Overview and Market Position
Alamar Biosciences, Inc. is a commercial-stage precision proteomics company based in Fremont, California. The company develops and sells an integrated platform built around its proprietary NULISA (Nucleic Acid Linked Immuno-Sandwich Assay) technology and the ARGO HT System, a fully automated instrument designed to detect and quantify protein biomarkers at extremely low concentrations in blood and other biological fluids.
Alamar's offering spans instruments, consumables, and analytical software, serving academic and research institutions, biopharmaceutical companies, contract research organizations, and service laboratories. Its applications cut across immunology, neurology, and oncology, with a particular focus on early disease detection, including blood-based biomarker research for Alzheimer's disease and related dementias.
The company completed its initial public offering on April 17, 2026, pricing shares at $17.00. It has since established partnerships aimed at advancing translational research in neurodegenerative disease, including collaborations focused on Alzheimer's disease biomarkers. Investors follow the stock for its position in the rapidly expanding precision proteomics and early-detection diagnostics market.
Alamar Biosciences (ALMR) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, Alamar shares declined approximately 19%, falling from a closing price of $34.85 on September 18, 2026, to $28.16 as of the latest session. The move was not a straight line down. The stock climbed to a record intraday high of $39.61 in early October before reversing sharply, sliding into the low-to-mid $20s around the lock-up expiry date of October 14, and then partially recovering into the high $20s.
The quarterly picture is more nuanced. From roughly $25 in late July, the stock rallied more than 50% at its peak before giving back most of those gains. Over the trailing three months, the shares finished modestly higher, reflecting a strong advance in August and September that was largely unwound by the October pullback. The overall pattern is one of elevated volatility around a fundamentally improving business, punctuated by a sharp correction tied to the release of restricted shares.
What Drove ALMR Stock Price in the Last 30 Days
The dominant force behind the 30-day decline was the expiration of Alamar's six-month IPO lock-up period on October 14, 2026. When a company goes public, pre-IPO investors and insiders are typically restricted from selling for a set period. As that window approached, the market began pricing in the prospect of a larger supply of shares becoming available, and selling pressure accelerated in the week leading up to the expiration. The stock fell more than 13% in a single session in early October as investors braced for the event.
Around the lock-up expiration, major pre-IPO backer Qiming Venture Partners filed notices of its intent to sell restricted shares and subsequently reported sales of additional shares. These disclosures were routine post-lock-up procedures, but they reinforced the supply overhang narrative at a time when the stock was already trading well above its IPO price.
Importantly, the decline also followed a period of very strong gains. Alamar shares had nearly doubled from their offering price, driven by accelerating revenue growth, positive news flow around its technology in Alzheimer's biomarker research, and a leadership expansion that included the appointment of a former diagnostics industry executive to its board. Against that backdrop, the October pullback reflected profit-taking and pre-lock-up positioning more than any deterioration in the company's operations.
What Drove ALMR Stock Performance Over the Last Quarter
The broader multi-month narrative is one of a fast-growing diagnostics company that rallied sharply on execution and then consolidated. During the quarter, Alamar reported second-quarter revenue of $29.4 million, an 82% increase from the prior year, with consumables revenue growing 147% and gross margin reaching roughly 60%. Management also issued full-year 2026 revenue guidance of $116 million to $120 million, implying continued strong growth.
That fundamental momentum, combined with positive developments such as a published study using its technology to evaluate Alzheimer's disease biomarkers and a national-scale research initiative in neurodegenerative disease, helped drive the stock toward record highs. The subsequent pullback around the lock-up expiration reversed much of that appreciation, leaving the stock roughly flat to modestly higher over the full quarter despite the elevated intraday peak.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots from a much larger universe of tools that monitor thousands of tickers across the market. The section highlights only the top-performing and most relevant bots at any given time, helping traders filter out noise and focus on strategies with demonstrated traction. These bots differ in their underlying approach, trading timeframe, and performance metrics, so what appears in the trending list can vary as market conditions shift. For investors seeking an additional, data-driven perspective on names like Alamar Biosciences and beyond, exploring the currently featured bots can offer a useful complement to fundamental research.
ALMR Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most immediate catalyst is Alamar's third-quarter 2026 earnings report, scheduled for November 3, 2026, which will provide updated detail on instrument placements, consumables pull-through, gross margin, and whether the company reaffirms its full-year revenue guidance. Investors will also be watching how the newly unlocked float is absorbed, as additional share sales by early backers could continue to pressure the stock in the near term.
Beyond the quarter, key drivers include the pace of adoption of the NULISA platform and ARGO HT System, expansion of the installed base and recurring consumables revenue, and progress toward regulatory and diagnostic applications. Broader factors such as research funding trends, demand for liquid-biopsy and proteomics tools, and the general risk appetite for early-stage, unprofitable life-sciences companies will also influence sentiment. As with any high-growth diagnostics company, execution against guidance and the trajectory of cash burn remain central considerations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ALMR sees its Stochastic Oscillator climbs out of oversold territory
On October 20, 2026, the Stochastic Oscillator for ALMR moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 4 instances where the indicator left the oversold zone. In 4 of the 4 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on ALMR as a result. In 8 of 8 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for ALMR just turned positive on October 21, 2026. Looking at past instances where ALMR's MACD turned positive, the stock continued to rise in 2 of 2 cases over the following month. The odds of a continued upward trend are 90%.
ALMR moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +19.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALMR advanced for three days, in 30 of 32 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
ALMR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day RSI Indicator for ALMR moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 5 similar instances where the indicator moved out of overbought territory. In 5 of the 5 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALMR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for ALMR entered a downward trend on September 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.976) is normal, around the industry mean (2.923). P/E Ratio (-43.943) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (20.367) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. ALMR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 78 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALMR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices